Cipla’s arm inks definitive agreement with Pulmatrix

16 Apr 2019 Evaluate

Cipla’s subsidiary -- Cipla Technologies LLC and Pulmatrix, Inc., a clinical stage biopharmaceutical company has entered into a definitive agreement for the co-development and commercialization of Pulmazole (PUR1900) - an inhaled iSPERSE formulation of the antifungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.

Following the Definitive Agreement, Cipla Technologies will make an upfront payment of $22 million to Pulmatrix in exchange for assignment of all rights for Pulmazole in relation to pulmonary indications to Cipla Technologies. Thereafter, both parties will equally share costs related to the future development and commercialization of Pulmazole, and equally share worldwide free cash flow from future sales of Pulmazole.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1405.95 49.00 (3.61%)
15-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1528.20
Dr. Reddys Lab 5872.35
Cipla 1405.95
Zydus Lifesciences 997.45
Lupin 1638.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.